每经AI快讯，泰恩康（SZ 301263，收盘价：28.5元）11月21日晚间发布公告称，广东泰恩康医药股份 有限公司（以下简称"公司"）于近日收到公司控股股东、实际控制人孙伟文女士的通知，获悉其所持有 的公司部分股份办理了解除质押的手续，本次解除质押股份数量为672万股。截至本公告日，郑汉杰累 计质押股数为3550万股，占其所持股份比例为40.17%。孙伟文累计质押股数为790万股，占其所持股份 比例为11.93%。 每经头条（nbdtoutiao）——展望"十五五" | 专访黄群慧：既要重视AI赋能千行百业，也要考量其对就业 的替代效应和带来的收入极化 （记者 曾健辉） 2024年1至12月份，泰恩康的营业收入构成为：医药代理占比61.1%，医药制造占比37.28%，医药技术 服务占比1.51%，其他业务占比0.12%。 截至发稿，泰恩康市值为121亿元。 ...

Group 1 - The core point of the article is that Hite Bio (SZ 300683) held its fifth meeting of the ninth board of directors on October 22, 2025, where it reviewed documents including the "Audit Committee Work Rules" [1] - For the first half of 2025, Hite Bio's revenue composition was as follows: 51.82% from pharmaceutical technology services, 37.87% from biopharmaceuticals, 9.49% from raw materials and pharmaceutical intermediates, 0.7% from in vitro diagnostic reagents, and 0.11% from other industries [1] - As of the report date, Hite Bio's market capitalization was 4.5 billion yuan [1]

Core Viewpoint - *ST Guohua announced the convening of its 2025 seventh temporary board meeting, discussing the proposal for the first temporary shareholders' meeting of 2025, indicating ongoing corporate governance activities [1] Financial Performance - For the first half of 2025, *ST Guohua's revenue composition was as follows: mobile network security accounted for 82.23%, medical technology services for 12.49%, other services for 3.65%, and emergency industry for 1.64% [1] - The company's market capitalization is currently 1.4 billion yuan [1]